Neuropsychological Considerations for Parkinson’s Disease Patients Being Considered for Surgical Intervention with Deep Brain Stimulation

  • Paul J. Mattis
  • Chaya B. Gopin
  • Kathryn Lombardi Mirra
Part of the Clinical Handbooks in Neuropsychology book series (CHNEURO)


In addition to their motor symptoms, patients diagnosed with idiopathic Parkinson’s disease (PD) often exhibit a subcortical pattern of cognitive impairment. Deep brain stimulation (DBS) is one of the treatments used to improve motor functioning in PD patients; however, studies focusing on the effects of DBS on cognition, mood, and behavior have produced mixed findings. This chapter reviews the history of various treatments for PD, the recent literature regarding DBS, and the neuropsychological outcomes in patients who undergo such surgery for the treatment of parkinsonian motor symptoms. DBS as a treatment for several other neurologic and psychiatric disorders is also discussed. In addition, case examples and recommendations for the neuropsychologist are presented.


Parkinson’s disease Surgery Ablative Deep brain stimulation Fetal transplantation Gene therapy Subcortical Subthalamic nucleus Globus pallidus 


  1. 1.
    Woods SP, Fields JA, Troster AI. Neuropsychological sequelae of subthalamic nucleus deep brain stimulation in Parkinson’s disease: a critical review. Neuropsychol Rev. 2002;12:111–26.PubMedGoogle Scholar
  2. 2.
    Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22:1689–707.PubMedGoogle Scholar
  3. 3.
    Pallone JA. Introduction to Parkinson’s disease. Disease-A-Month. 2007;53:195–9.PubMedGoogle Scholar
  4. 4.
    Olanow CW, Stern MB. Parkinson’s disease: unresolved issues. Ann Neurol. 2008;64:S1–2.PubMedGoogle Scholar
  5. 5.
    Rosenthal A. Auto transplants for Parkinson’s disease? Neuron. 1998;20:169–72.PubMedGoogle Scholar
  6. 6.
    Rothstein TL, Olanow CW. The neglected side of Parkinson’s disease. Am Sci. 2008;96:218–25.Google Scholar
  7. 7.
    Youdim MB, Riederer P. Understanding Parkinson’s disease. Sci Am. 1997;1:52–9.Google Scholar
  8. 8.
    DeLong M, Wichmann T. Update on models of basal ganglia function and dysfunction. Parkinsonism Relat Disord. 2009;15:S239–40.Google Scholar
  9. 9.
    Torres G, Fraley GS, Hallas BH, Leheste JR, Phillippens I. New frontiers in Parkinson’s disease therapy: deep brain stimulation. Kopf Carrier. 2010; 69:1–8. Retrieved from
  10. 10.
    Fernandez HH, See RH, Gary MF, Bowers D, Rodriguez RL, Jacobson C, Okun MS. Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performance. J Geriatr Psychiatry Neurol. 2009;22:223–7.PubMedGoogle Scholar
  11. 11.
    Cozzens JW. Surgery for Parkinson’s disease. Disease-A-Month. 2007;53:227–42.PubMedGoogle Scholar
  12. 12.
    Henderson JM, Dunnett SB. Targeting the subthalamic nucleus in the treatment of Parkinson’s disease. Brain Res Bull. 1998;46:467–74.PubMedGoogle Scholar
  13. 13.
    Pollak P, Benabid AL, Gross C, Gao DM, Laurent A, Benazzouz A, Hoffmann D, Gentil M, Perret J. Effects of the stimulation of the subthalamic nucleus in Parkinson’s disease. Rev Neurol. 1993;149:175–6.PubMedGoogle Scholar
  14. 14.
    Fahn S. How do you treat motor complications in Parkinson’s disease: Medicine, surgery, or both? Ann Neurol. 2008;64:S56–64.PubMedGoogle Scholar
  15. 15.
    Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000;123:2297–305.PubMedGoogle Scholar
  16. 16.
    Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson’s disease. Lancet Neurol. 2008;7:927–38.PubMedGoogle Scholar
  17. 17.
    Rezai AR, Machado AG, Deogaonkar M, Azmi H, Kubu C, Boulis NM, et al. Surgery for movement disorders. Neurosurgery. 2008;62:S809–39.Google Scholar
  18. 18.
    Espay AJ, Mandybur GT, Revilla FJ. Surgical treatment of movement disorders. Clin Geriatr Med. 2006;22:813–25.PubMedGoogle Scholar
  19. 19.
    Gildernberg PL. Management of movement disorders. An overview. Neurosurg Clin N Am. 1995;6:43–53.Google Scholar
  20. 20.
    Fields JA, Troster A. Cognitive outcomes after deep brain stimulation for Parkinson’s disease: a review of initial studies and recommendations for future research. Brain Cogn. 2000;42:268–93.PubMedGoogle Scholar
  21. 21.
    Cooper O, Astradsson A, Hallett P, Robertson H, Mendez I, Isacson O. Lack of functional relevance of isolated cell damage in transplants of Parkinson’s disease patients. J Neurol. 2009;256:S310–316.Google Scholar
  22. 22.
    Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson’s disease. Trends Neurosci. 1996;19:102–9.PubMedGoogle Scholar
  23. 23.
    Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranth C, Roth RH, Price LH, Gjedde A, Bunney BS, Sass KJ, Elsworth JD, Kier L, Majuch R, Hoffer PB, Redmond DE. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson’s disease. N Engl J Med. 1992;327:1541–8.PubMedGoogle Scholar
  24. 24.
    Olanow CW, Fahn S. Fetal nigral transplantation as a therapy for Parkinson’s disease. In: Brundin P, Olanow CW, editors. Restorative therapist in Parkinson’s disease. New York, NY: Springer Science  +  Business Media, LLC; 2006. p. 93–118.Google Scholar
  25. 25.
    Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, Freed C, Dhawan V, Eidelberg D. Dopamine cell implantation in Parkinson’s disease: Long-term clinical and 18F-FDOPA PET outcomes. J Nucl Med. 2010;51:7–15.PubMedGoogle Scholar
  26. 26.
    Trott CT, Fahn S, Greene P, Dillon S, Winfield H, Winfield L, Kao R, Eidelberg D, Freed CR, Breeze RE, Stern Y. Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study. Neurology. 2003;60(12):1938–43.PubMedGoogle Scholar
  27. 27.
    Kaplitt MG, Feigin A, Tang C, Fitzsimons H, Mattis P, Lawlor PA, Bland RJ, Young B, Strybing K, Eidelberg D, During MJ. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet. 2007;369:2097–105.PubMedGoogle Scholar
  28. 28.
    Mattis P, Zgaljardic D, Feigin A. Neuropsychological functioning in pre-symptomatic but gene positive patients with Huntington’s disease. J Int Neuropsychol Soc. 2002;8:276.Google Scholar
  29. 29.
    Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Marcias R, Alvarez L, Guridi J, Vitek J, Delong MR. Pathophysiologic basis of surgery for Parkinson’s disease. Neurology. 2000;55:S7–S12.PubMedGoogle Scholar
  30. 30.
    Wichmann T, DeLong MR. Pathophysiology of Parkinson’s disease: the MPTP primate model of the human disorder. Ann N Y Acad Sci. 2003;991:199–213.PubMedGoogle Scholar
  31. 31.
    Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ. Two genes encode distinct glutamate decarboxylases. Neuron. 1991;7:91–100.PubMedGoogle Scholar
  32. 32.
    Emborg ME, Carbon M, Holdern JE, During MJ, Ma Y, Tang C, Moirano J, Fitzsimons J, Roitberg BZ, Tuccar E, Roberts A, Kaplitt MG, Eidelberg D. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab. 2007;27:501–9.PubMedGoogle Scholar
  33. 33.
    Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O’Malley KL, During MJ. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet. 1994;8:148–54.PubMedGoogle Scholar
  34. 34.
    Lee B, Lee H, Nam YR, Oh JH, Cho YH, Chang JW. Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. Gene Ther. 2005;12:1215–22.PubMedGoogle Scholar
  35. 35.
    Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, During MJ. Subthalamic GAD gene therapy in a Parkinson’s disease rat model. Science. 2002;298:425–9.PubMedGoogle Scholar
  36. 36.
    Dormont D, Seidenwurm D, Galanaud D, Cornu P, Yelnik J, Bardinet E. Neuroimaging and deep brain stimulation. Am J Neuroradiol, 2010; 15–23.Google Scholar
  37. 37.
    Benabid AL, Chabardes S, Seigneuret E. Deep-brain stimulation in Parkinson’s disease: long-term efficacy and safety—What happened this year? Curr Opin Neurol. 2005;18:623–30.PubMedGoogle Scholar
  38. 38.
    Okun MS, Rodriguez RL, Miller AMK, Kellison I, Kirsch-Darrow L, Wint DP, Springer U, Fernandez HH, Foote KD, Crucian G, Bowers D. Deep brain stimulation and the role of the neuropsychologist. Clin Neuropsychol. 2007;21:162–89.PubMedGoogle Scholar
  39. 39.
    Vitek JL. Deep brain stimulation: how does it work? Cleveland Clinical J Med. 2008;75:S59–65.Google Scholar
  40. 40.
    Pourfar M, Tang C, Lin T, Dhawan V, Kaplitt MG, Eidelberg D. Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. J Neurosurg. 2009;110:1278–82.PubMedGoogle Scholar
  41. 41.
    Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, Kaplitt MG, Feigin A, Eidelberg D. Network modulation in the treatment of Parkinson’s disease. Brain. 2006;129:2667–78.PubMedGoogle Scholar
  42. 42.
    Chang J. Brain Stimulation for neurological and psychiatric disorders, current status and future direction. J Pharmacol Exp Ther. 2004;309:1–7.PubMedGoogle Scholar
  43. 43.
    Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ. “Rejuvenation” projects neurons in mouse models of Parkinson’s disease. Nature. 2007;447:1081–5.PubMedGoogle Scholar
  44. 44.
    Histed MH, Bonin V, Reid RC. Direct activation of sparse, distributed populations of cortical neurons by electrical micro-stimulation. Neuron. 2009;63:508–22.PubMedGoogle Scholar
  45. 45.
    Volkmann J, Allert N, Voges J, Sturn V, Schnitzler A, Freund H. Long term results of bilateral pallidal stimulation in Parkinson’s disease. Ann Neurol. 2004;55:871–5.PubMedGoogle Scholar
  46. 46.
    Machado A, Rezai AR, Kopell BH, Gross RE, Sharan AD, Benabid A. Deep brain stimulation for Parkinson’s disease: surgical technique and perioperative management. Mov Disord. 2006;21:S247–58.PubMedGoogle Scholar
  47. 47.
    Schweder PM, Hansen PC, Green AL, Quaghebeur G, Stein J, Aziz TZ. Connectivity of the pedunculopontine nucleus in parkinsonian freezing of gait. NeuroReport: For Rapid Communication of Neuroscience Research. 2010;21:914–6.Google Scholar
  48. 48.
    Morrison CE, Borod JC, Perrine K, Beric A, Brin MF, Rezai A, Kelly P, Sterio D, Germano I, Weisz D, Olanow CW. Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson’s disease. Arch Clin Neuropsychol. 2002;19:165–81.Google Scholar
  49. 49.
    St George RJ, Nutt JG, Burchiel KJ, Horak FB. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology. 2010;75:1292–9.PubMedGoogle Scholar
  50. 50.
    Moro E, Scerrati M, Romito LMA, Roselli R, Tonali P, Albanese A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson’s disease. Neurology. 1999;53:85–90.PubMedGoogle Scholar
  51. 51.
    Moro E, Hamani C, Poon Y, Al-Khairallah T, Dostrovsky JO, Hutchinson WD, Lozano AM. Unilateral pedunculopontine stimulation improves falls in Parkinson’s disease. Brain. 2010;133:215–24.PubMedGoogle Scholar
  52. 52.
    Schupbach WMM, Chastan N, Welter ML, Houeto JL, Mesnage V, Bonnet AM, Czernecki V, Maltete D, Hartmann A, Mallet L, Pidoux B, Dormont D, Navarro S, Cornu P, Mallet A, Agid Y. Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up. J Neurol Neurosurg Psychiatry. 2005;76: 1650–44.Google Scholar
  53. 53.
    Parsons TD, Rogers SA, Broaten AJ, Woods SP, Troster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson’s disease: a meta-analysis. Lancet Neurol. 2006;5:578–88.PubMedGoogle Scholar
  54. 54.
    Jahanshahi M, Ardouin CMA, Brown RG, Rothwell JC, Obeso J, Albanese A, Rodriguez-Oroz MC, Moro E, Benabid AL, Pollak P, Lomousin-Dowsey P. The impact of deep brain stimulation on executive function in Parkinson’s disease. Brain. 2000;123: 1142–54.PubMedGoogle Scholar
  55. 55.
    Saint-Cyr JA, Trepanier LL, Kumar R, Lozano AM, Lang AE. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson’s disease. Brain. 2000;123:2091–108.PubMedGoogle Scholar
  56. 56.
    Ashby P, Kim YJ, Kumar R, Lang AE, Lozano AM. Neurophysiological effects of stimulation through electrodes in the human subthalamic nucleus. Brain. 1999;122:1919–31.PubMedGoogle Scholar
  57. 57.
    Dujardin K, Defebvre L, Krystkowiak P, Blond S, Destee A. Influence of chronic bilateral stimulation of the subthalamic nucleus on cognitive function in Parkinson’s disease. J Neurol. 2001;248:603–11.PubMedGoogle Scholar
  58. 58.
    Pillon B, Ardouin C, Damier P, Krack P, Houeto JL, Klinger H, Bonnet AM, Pollak P, Benabid AL, Agid Y. Neuropsychological changes between “off” and “on” STN or GPi stimulation in Parkinson’s disease. Neurology. 2000;55:411–8.PubMedGoogle Scholar
  59. 59.
    York MK, Dulay M, Macias A, Levin HS, Grossman R, Simpson R, Jankovic J. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2008;79:789–95.PubMedGoogle Scholar
  60. 60.
    Perriol MP, Krystkowiak P, Defebvre L, Blond S, Destee A, Dujardin K. Stimulation of the subthalamic nucleus in Parkinson’s disease: Cognitive and affective changes are not linked to the motor outcome. Parkinsoniam Relat Disord. 2006;12:205–10.Google Scholar
  61. 61.
    Hariz MI, Johansson F, Shamsgovara P, Johansson E, Hariz GM, Fagerlund M. Bilateral subthalamic nucleus stimulation in parkinsonian patient with preoperative deficits in speech and cognition: Persistent improvement in mobility but increased dependency: A case study. Movement Disoders. 2000;15:136–9.Google Scholar
  62. 62.
    Trepanier LL, Kumar R, Lozano AM, Lang AE, Saint-Cyr JA. Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson’s disease. Brain Cogn. 2000;42:324–47.PubMedGoogle Scholar
  63. 63.
    Perozzo P, Rizzone M, Bergamasco B, Castelli L, Lanotte M, Tavella A, Torre E, Lopiano L. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: comparison of pre- and postoperative neuropsychological evaluation. J Neurol Sci. 2001;192:9–15.PubMedGoogle Scholar
  64. 64.
    Smeding HMM, Speelman JD, Koning-Haanstra M, Schuurman PR, Nijssen P, Van Laar T, Schmand B. Neuropsychological effects of bilateral STN stimulation in Parkinson’s disease: a controlled study. Neurology. 2006;66:1830–6.PubMedGoogle Scholar
  65. 65.
    Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H, Chabardes S, Foote K, Benabid AL, Pollak P. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75:834–9.PubMedGoogle Scholar
  66. 66.
    Kulisevsky J, Berthier ML, Gironell A, Gironell A, Pascual-Sedano B, Molet J, Pares P. Secondary mania following subthalamic nucleus deep brain stimulation for the treatment of Parkinson’s disease [abstract]. Neurology. 2001;56:S49.Google Scholar
  67. 67.
    Krack P, Kumar R, Ardouin C, Limousin-Dowsey P, McVicker JM, Benabid AL, Pollak P. Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord. 2001;16:867–75.PubMedGoogle Scholar
  68. 68.
    Diederich NJ, Alesch F, Goetz CG. Visual hallucinations induced by deep brain stimulation in Parkinson’s disease. Clin Neuropharmacol. 2000;23:287–9.PubMedGoogle Scholar
  69. 69.
    Castelli L, Perozzo P, Zibetti M, Crivelli B, Morabito U, Lanotte M, Cossa F, Bergamasco B, Lopiano L. Chronic deep brain stimulation of the subthalamic nucleus for Parkinson’s disease: Effects on cognition, mood, anxiety and personality traits. Eur Neurol. 2006;55:136–44.PubMedGoogle Scholar
  70. 70.
    Daniele A, Albanese A, Contarino MF, Zinzi P, Barbier A, Gasparini F, Romito LMA, Bentivoglio AR, Scerrati M. Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74:175–82.PubMedGoogle Scholar
  71. 71.
    Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO, Krause M, Tronnier V, Kloss M, Schnitzler A, Wojtecki L, Botzel K, Danek A, Hilker R, Sturm V, Kupsch A, Karner E, Deuschl G. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomized, multicentre study. Lancet Neurol. 2008;7:605–14.PubMedGoogle Scholar
  72. 72.
    Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schupbach M, et al. A multicentre study on suicide outcome following subthalamic stimulation for Parkinson’s disease. Brain. 2008;131:2720–8.PubMedGoogle Scholar
  73. 73.
    Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki V, Hosseini H, et al. Pathological gambling in parkinon’s disease improves on chronic subthalamic nucleus stimulation. Mov Disord. 2006;21:1941–6.PubMedGoogle Scholar
  74. 74.
    Brun DJ, Troster AI. Neuropsychiatric complications of medical and surgical therapies for Parkinson’s disease. J Geriatr Psychiatry Neurol. 2004;17:172–80.Google Scholar
  75. 75.
    Papapetropoulos S, Katzen H, Schrag A, Singer C, Scanlon BK, Nation D, Guevara A, Levin B. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson’s disease. BMC Neurol. 2008;8:21.PubMedGoogle Scholar
  76. 76.
    Yoshida F, Miyagi Y, Kishimoto J, Morioka T, Murakami N, Hashiguchi K, Samura K, et al. Subthalamic nucleus stimulation does not cause deterioration of preexisting hallucinations in Parkinson’s disease patients. Sterotact Funct Neurosurg. 2009;87:45–9.Google Scholar
  77. 77.
    Siderowf A, Jaggi JL, Xie SX, Loveland-Jones C, Leng L, Hurtig H, Colcher A, Stern M, Chou KL, Liang G, Maccarone H, Simuni T, Baltuch G. Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson’s disease. Mov Disord. 2006;21:746–53.PubMedGoogle Scholar
  78. 78.
    Lezcano E, Gomez-Esteban JC, Zarranz JJ, Lambarri I, Madoz P, Bilbao G, Pomposo I, Garibi J. Improvement in quality of life in patients with advanced Parkinson’s disease following bilateral deep-brain stimulation in subthalamic nucleus. Eur J Neurol. 2004;11:451–4.PubMedGoogle Scholar
  79. 79.
    Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 2003;349:1925–34.PubMedGoogle Scholar
  80. 80.
    Den Oudsten BL, Van Heck GL, De Vries J. Quality of life and related concepts in Parkinson’s disease: a systemic review. Mov Disord. 2007;22:1528–37.Google Scholar
  81. 81.
    Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry. 2005;76:188–1193.Google Scholar
  82. 82.
    Martinez-Martin P, Deuschl G. Effect of medical and surgical interventions on health-related quality of life in Parkinson’s disease. Mov Disord. 2007;22:757–65.PubMedGoogle Scholar
  83. 83.
    Antonini A, Landi A, Mariani C, DeNotaris R, Pezzoli G. Deep brain stimulation and its effect on sleep in Parkinson’s disease. Sleep Med. 2004;5:211–4.PubMedGoogle Scholar
  84. 84.
    Cicolin A, Lopiano L, Zibetti M, Torre E, Tavella A, Guastamacchia G, Terreni A, Makrydakis G, Fattori E, Lanotte MM, Bergamasco B, Mutani R. Effects of deep brain stimulation on the subthalamic nucleus on sleep architecture in parkinsonian patients. Sleep Med. 2004;5:207–10.PubMedGoogle Scholar
  85. 85.
    Pillon B. Neuropsychological assessment for management of patients with deep brain stimulation. Mov Disord. 2002;17:S116–22.PubMedGoogle Scholar
  86. 86.
    Pillon B, Dubois B, Agid Y. Testing cognition may contribute to the diagnosis of movement disorders. Neurology. 1996;46:329–33.PubMedGoogle Scholar
  87. 87.
    Mattis S. Dementia rating scale. Odessa, FL: Psychological Assessment Resources; 1988.Google Scholar
  88. 88.
    Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol. 1987;3:13–36.Google Scholar
  89. 89.
    Kaplan EF, Goodglass H, Weintraub S. The Boston Naming Test. 2nd ed. Philadelphia, PA: Lea and Febiger; 1983.Google Scholar
  90. 90.
    Heilman KM, Gonzalez Rothi LJ. Apraxia. In: Heilman KM, Valenstein E, editors. Clinical Neuropsychology. 2nd ed. Oxford, England: Oxford University; 2003. p. 215–35.Google Scholar
  91. 91.
    Meyers J, Meyers K. The Meyers scoring system for the Rey Complex Figure and the Recognition Trial: professional manual. Odessa, FL: Psychological Assessment Resources; 1995.Google Scholar
  92. 92.
    Montgomery SA, Asberg MA. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.PubMedGoogle Scholar
  93. 93.
    Jurica PJ, Leitten CL, Mattis S. Dementia Rating Scale-2: professional manual. Lutz: Psychological Assessment Resources; 2001.Google Scholar
  94. 94.
    Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.PubMedGoogle Scholar
  95. 95.
    Wechsler D. Wechsler Abbreviated Scales of Intelligence. San Antonio, TX: Psychological Corporation; 1999.Google Scholar
  96. 96.
    Gronwall DM. Paced Auditory Serial Addition Task: a measure of recovery from concussion. Percept Mot Skills. 1977;44:363–73.Google Scholar
  97. 97.
    Brandt J, Benedict RHB. The Hopkins Verbal Learning Test Revised: professional manual. Odessa, FL: Psychological Assessment Resources; 2002.Google Scholar
  98. 98.
    Wechsler D. Wechsler Memory Scale: manual. 3rd ed. San Antonio, TX: Psychological Corporation; 1997.Google Scholar
  99. 99.
    Benton AL, Hamsher K, Sivan AB. Multilingual Aphasia Examination—Third Edition. 3rd ed. Iowa City, IA: AJA Associates; 1983.Google Scholar
  100. 100.
    Benton AL, Hamsher K, Varney NR, Spreen O. Contributions to Neuropsychological Assessment. A clinical manual. New York, NY: Oxford University; 1983.Google Scholar
  101. 101.
    Golden CJ. Stroop Color and Word Test: a manual for clinical and experimental uses. Cleveland, OH: Stoelting Co; 1978.Google Scholar
  102. 102.
    Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio, TX: Psychological Corporation; 1997.Google Scholar
  103. 103.
    Randt CT, Brown ER. Administration Manual: Randt Memory Test. Bayport, NY: Life Science Associates; 1983.Google Scholar
  104. 104.
    Smith A. Symbol Digit Modalities Test: manual. Los Angeles, CA: Western Psychological Services; 1982.Google Scholar
  105. 105.
    Kongs SK, Thompson LL, Iverson GL, Heaton RK. Wisconsin Card Sorting Test-64 Card Version. Lutz, FL: Psychological Assessment Resources; 2000.Google Scholar
  106. 106.
    Luria AR. Higher Cortical Functions in Man. New York, NY: Basic Books; 1980.Google Scholar
  107. 107.
    Grace J, Malloy P. Frontal Systems Behavior Scale (FrSBe): professional manual. Lutz, FL: Psychological Assessment Resources; 2001.Google Scholar
  108. 108.
    Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test-Second Edition, Adult Version manual. San Antonio, TX: The Psychological Corporation; 2000.Google Scholar
  109. 109.
    Benedict RHB. Brief Visuospatial Memory Test-Revised: manual. Odessa, FL: Psychological Assessment Resources; 1997.Google Scholar
  110. 110.
    Goodglass H, Kaplan E. Boston diagnostic aphasia examination. Philadelphia, PA: Lea and Febiger; 1983.Google Scholar
  111. 111.
    Hooper H. Hooper Visual Organization Test (HVOT). Los Angeles: Western Psychological Services; 1983.Google Scholar
  112. 112.
    Beck AT, Steer RA, Brown GK. BDI-II, Beck depression inventory: manual. 2nd ed. Boston, MA: Harcourt Brace; 1996.Google Scholar
  113. 113.
    Beck AT, Steer RA. Beck anxiety inventory: manual. San Antonio, TX: Psychological Corporation; 1990.Google Scholar
  114. 114.
    Deuschel G, Wenzelburger R, Loffler K, Raethjen J, Stolze H. Essential tremor and cerebellar dysfunction clinical and kinematic analysis of intention tremor. Brain. 2000;123:1568–80.Google Scholar
  115. 115.
    Louis ED, Ford B, Wendt KJ, Cameron G. Clinical characteristics of essential tremor: data from a community-based study. Mov Disord.1998;13:803–8.Google Scholar
  116. 116.
    Deuschl G, Bain P. Deep brain stimulation for trauma: patient selection and evaluation. Mov Disord. 2002;17:S102–11.PubMedGoogle Scholar
  117. 117.
    Pollak P, Benabid AL, Krack P, Lomousin P, Benazzouz A. Deep brain stimulation. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Baltimore, MD: Williams and Wilkoins; 1998. p. 1085–102.Google Scholar
  118. 118.
    Pahwa R, Lyons KL, Wilkonson SB, Carpenter MA, Troster AI, Searl JO, Overman J, Pickering S, Koller WC. Bilateral thalamic stimulation for the treatment of essential tremor. Neurology. 1999;53:1447–50.PubMedGoogle Scholar
  119. 119.
    Schuurman PR, Bosch DA, Bossuyt PM, Bonsel GJ, van Someren EJ, de Bie RM, Merkus MO, Speelman JD. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med. 2000;342:461–8.PubMedGoogle Scholar
  120. 120.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000. p. 111–4.Google Scholar
  121. 121.
    Serrvello D, Sassi M, Porta M. Deep brain stimulation in Tourette syndrome. Clin Neuropsychiatry. 2009;6:266–73.Google Scholar
  122. 122.
    Temel Y, Visser-Vandewalle V. Surgery in Tourette syndrome. Mov Disord. 2004;19:3–14.PubMedGoogle Scholar
  123. 123.
    Houeto JL, Karachi C, Mallet L, Pillon B, Yelnik J, Mesnage V, Welter ML, Navarro S, Pelissolo A, Damier P, Pidoux B, Dormont D, Cornu P, Agid Y. Tourette’s syndrome and deep brain stimulation. J Neurol Neurosurg Psychiatry. 2005;76: 992–5.PubMedGoogle Scholar
  124. 124.
    Servello D, Porta M, Sassi M, Brambilla A, Robertson MM. Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: the surgery and stimulation. J Neurol Neurosurg Psychiatry. 2008;79:136–42.PubMedGoogle Scholar
  125. 125.
    Alterman RL, Dumitriu D, Mathew S. Deep brain stimulation for major depressive disorder. Clin Neuropsychiatry. 2009;6:259–65.Google Scholar
  126. 126.
    Dowman J, Patel A, Rajput K. Electroconvulsive therapy: attitudes and misconceptions. J Electro-convulsive Therapy. 2005;21:84–7.Google Scholar
  127. 127.
    Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord. 2008;110:1–15.PubMedGoogle Scholar
  128. 128.
    Loo CK, MaFarquhar TF, Mitchell PB. A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression. Int J Neuropsychopharmacol. 2008;11:131–47.PubMedGoogle Scholar
  129. 129.
    Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66:522–6.PubMedGoogle Scholar
  130. 130.
    Jimenez F, Velasco F, Salin-Pascual R, Hernandez JA, Velasco M, Criales JL, Nicolini H. A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. Neurosurgery. 2005;57:585–93.PubMedGoogle Scholar
  131. 131.
    Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651–60.PubMedGoogle Scholar
  132. 132.
    Schlaepfer TE, Lieb K. Deep brain stimulation for treatment of refractory depression. Lancet. 2005;366:1420–2.PubMedGoogle Scholar
  133. 133.
    Lozano AM, Maybery HS, Giacobbe O, Hamani C, Craddock RC, Kennedy SH. Subcallosal cingulated gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry. 2008;64:461–7.PubMedGoogle Scholar
  134. 134.
    Malone Jr DA, Doughtery DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN, Rauch SL, Rasmussen SA, Machado AG, Jubu CS, et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry. 2009;65:267–75.PubMedGoogle Scholar
  135. 135.
    Wang X, Chang C, Geng N, Li N, Wang J, Ma J, Xue W, Zhao W, Wu H, Wang P, Gao G. Long-term effects of bilateral deep brain stimulation of the subthalamic nucleus on depression in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:587–91.PubMedGoogle Scholar
  136. 136.
    Lakhan SE, Callaway E. Deep brain stimulation for obsessive-compulsive disorder and treatment-resistant depression: systematic review. BMC Research Notes. 2010;3:60.PubMedGoogle Scholar
  137. 137.
    Nuttin B, Cosyns P, Demeulemeester H, Gybels J, Meyerson B. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet. 1999;354:1526.PubMedGoogle Scholar
  138. 138.
    Nuttin BJ, Gabriels LA, Cosyns PR, Meyerson BA, Andreewitch S, Sunaert SG, Maes AF, Dupont PJ, Gybels JM, Gilen F, Demeulemeester HG. Long-term electrical capsular simulation in patients with obsessive-compulsive disorder. Neurosurgery. 2003;52:1263–72.PubMedGoogle Scholar
  139. 139.
    Nuttin BJ, Gabriels LA, Cosyns PR, Meyerson BA, Andreewitch S, Sunaert SG, Maes AF, Dupont PJ, Gybels JM, Gielen F, Demeulemeester HG. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery. 2008;62:966–77.PubMedGoogle Scholar
  140. 140.
    Gabriels L, Cosyns P, Nuttin B, Demeulemeester H, Gybels J. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatr Scand. 2003;107:275–82.PubMedGoogle Scholar
  141. 141.
    Abelson JL, Curtis GC, Sagher O, Albucher RC, Harrigan M, Taylor SF, Martis B, Giordani B. Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry. 2005;57:510–6.PubMedGoogle Scholar
  142. 142.
    Sturm V, Lenartz D, Koulousakis A, Treuer H, Herholz K, Klein JC, Klosterkotter J. The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorder. J Chem Neuroanat. 2003;26:293–9.PubMedGoogle Scholar
  143. 143.
    Aouizerate B, Cuny E, Bardinet E, Yelnik J, Martin-Guehl C, Rotge JY, Rougier A, Bioulac B, Tignol J, Mallet L, et al. Distinct striatal targets in treating obsessive-compulsive disorder and major depression. J Neurosurg. 2009;111:775–9.PubMedGoogle Scholar
  144. 144.
    Jimenez F, Velasco F, Salin-Pascual R, Velasco M, Nicolini H, Velasco AL, Castro G. Neuromodulation of the inferior thalamic peduncle for major depression and obsessive compulsive disorder. Acta Neurochir. 2007;97:S393–8.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Paul J. Mattis
    • 1
    • 2
  • Chaya B. Gopin
    • 2
    • 3
  • Kathryn Lombardi Mirra
    • 2
    • 3
  1. 1.Center for NeurosciencesThe Feinstein Institute for Medical ResearchManhassetUSA
  2. 2.Department of NeurologyNorth Shore University HospitalManhassetUSA
  3. 3.Department of PsychiatryThe Zucker Hillside HospitalGlen OaksUSA

Personalised recommendations